Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.

ABSTRACT: This article provides an updated review of the pharmacological profile and available efficacy and tolerability/safety data for vilazodone, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vilazodone for MDD in adults is supported by four positive short-term (8-10 weeks), randomized, placebo-controlled trials. Beyond these pivotal trials, we review updated research findings pertaining to the clinical effects of vilazodone for MDD including the results of switch studies, small comparative efficacy trials, key pooled and secondary data analyses focused on important depressive subtypes (anxious depression) and predictors of treatment outcome, and safety studies including direct studies of sexua

SUBMITTER: Chauhan M 

PROVIDER: S-EPMC9206504 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature